Evotec SE (NASDAQ:EVO – Get Free Report) was the recipient of a large increase in short interest in the month of January. As of January 31st, there was short interest totalling 54,000 shares, an increase of 2,060.0% from the January 15th total of 2,500 shares. Currently, 0.0% of the company’s shares are short sold. Based on an average daily volume of 65,100 shares, the short-interest ratio is presently 0.8 days.
Analysts Set New Price Targets
Separately, Royal Bank of Canada upgraded Evotec from a “sector perform” rating to an “outperform” rating in a research report on Thursday, January 18th.
Evotec Stock Performance
Institutional Inflows and Outflows
A hedge fund recently bought a new stake in Evotec stock. Quadrant Capital Group LLC bought a new stake in shares of Evotec SE (NASDAQ:EVO – Free Report) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 2,130 shares of the company’s stock, valued at approximately $25,000. Institutional investors own 0.39% of the company’s stock.
Evotec Company Profile
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women's health.
- Five stocks we like better than Evotec
- How to Invest in Virtual Reality
- Wendy’s vs Shake Shack: Out with the new, in with the old?
- Mega Cap Stocks: What They Are and How to Invest
- Simpson Manufacturing stock doubled in value; It can double again
- What Are Dividend Achievers? An Introduction
- Uber quadruples EPS estimates, but is growth decelerating?
Receive News & Ratings for Evotec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evotec and related companies with MarketBeat.com's FREE daily email newsletter.